ERBA Diagnostics Enters Brazilian Sector with Leading-Edge Clinical Testing Portfolio
|
By LabMedica International staff writers Posted on 02 Nov 2014 |
|
ERBA Diagnostics, Inc. (Miami Lakes, FL, USA) has announced that an integrated portfolio of its latest in vitro diagnostics platforms and reagents are now being made available to hospitals, references labs, and physician clinics in Brazil. The product line includes a comprehensive suite of instruments, reagents, and kits for immunology, clinical chemistry, hematology, diabetes, and infectious disease testing, with an emphasis on hematology and clinical chemistry. ERBA Diagnostics intends to introduce this suite of products as the product registrations in Brazil are completed.
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gastrointestinal Panel
Xpert® GI Panel
Latest Industry News
- Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval
- Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
- Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
- New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing
- Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
- Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
- Sputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
- Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
- Unilabs Expands Digital Pathology Across European Network with Proscia Platform
- Digital Pathology Partnership Integrates Breast Cancer Diagnostic and Prognostic Tools
- MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
- Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
- Sepsis Diagnostics Market Growth Fueled by Faster Pathogen Detection Needs
- Project Advances Single-Cell Diagnostic Test for Triple-Negative Breast Cancer
- Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry
- Health Canada Licenses Point-of-Care Hematology Analyzer for Decentralized CBC Testing
Channels
Clinical Chemistry
view channel
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more
Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read moreMolecular Diagnostics
view channel
Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care
Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more
Molecular Skin Test May Help Guide Treatment Selection in Atopic Dermatitis
Patients with atopic dermatitis (eczema) often struggle to achieve consistent symptom control, leading many to alter or switch systemic therapies when treatment is ineffective. Newly published survey data... Read more
Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer
Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more
Genomic Breast Cancer Study Adds Real-World Evidence Across Diverse Patient Populations
Early-stage breast cancer treatment planning requires balancing recurrence risk, tumor biology, and the potential benefit of systemic therapy. These decisions can be challenging when certain patient groups... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
Microbiology
view channel
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more
Pathology
view channel
Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
Bleeding after menopause requires prompt investigation for uterine cancer, although most women who undergo testing do not have the disease. In the U.K., uterine cancer affects nearly 10,000 women each... Read more
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more
Technology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
